PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Sep 22, 2020

byprotokinetixp

dry-eye | Ocular inflammation

Dry Eye Disease: Investor Presentation

Dry eye disease (DED) is a multifactorial disease of the ocular surface which results in a spectrum of symptoms and/or signs that affect 5 30% of the population. Download our...Read more

Sep 21, 2020

byprotokinetixp

Seeking improved treatments for dry eye disease

A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including...Read more

Sep 15, 2020

bybhenderson

ProtoKinetix AAGP® Restores Vision in Blind Test Subjects

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of extensive testing, evidence of fully functional retinal cells was conclusively...Read more

Aug 27, 2020

bybhenderson

Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada

Marietta, Ohio, August 27, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that Dr. James Shapiro has received approval from Health Canada and the...Read more

Aug 21, 2020

byprotokinetixp

Invest in the potential of AAGP® for type-1 diabetes

While there is currently no cure for diabetes, we believe our anti-aging glycopeptide, AAGP®, may be the essential link to the successful treatments of tomorrow. In preliminary testing, AAGP® has been...Read more

Aug 14, 2020

bybhenderson

ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing

Marietta, Ohio, August 14, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due the results that AAGP® has achieved over the...Read more

Jul 20, 2020

byprotokinetixp

How world-renowned researchers are exploring a potential Type 1 diabetes cure

For anyone living with Type 1 diabetes, there is no doubt it is a challenging illness. Type 1 diabetes occurs at no fault of the patient, but unfortunately, there is...Read more

Jul 14, 2020

byprotokinetixp

Living with and Treating Type 1 Diabetes

When you are diagnosed with diabetes, you might initially feel overwhelmed and helpless. This chronic condition isn’t easy to live with all the time, since there are physical side effects...Read more

Jul 13, 2020

byprotokinetixp

Exploring a cure for diabetes

According to the Centers for Disease Control and Prevention (CDC), there were more than 30.3 million diagnosed cases of diabetes in the U.S. in 2015, and more than 100 million...Read more

Jul 13, 2020

bybhenderson

Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada

Marietta, Ohio, July 13, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of March 24, 2020. The amendments...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.